Related Experiment Video
Updated: Jun 13, 2026

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
Published on: April 3, 2018
Mutations in modified virus Ankara protein 183 render it a non-functional counterpart of B14, an inhibitor of nuclear
Laura E McCoy1, Aodhnait S Fahy, Ron A-J Chen
1Department of Virology, Imperial College London, London W2 1PG, UK.
Abstract:
Vaccinia virus (VACV) encodes multiple proteins to evade host innate immunity, including B14, a virulence factor that binds to the inhibitor of kappaB kinase beta (IKKbeta) and blocks nuclear factor kappaB (NF-kappaB) activation. B14 shares 95 % amino acid identity with the 183 protein encoded by modified virus Ankara (MVA), an attenuated VACV strain being developed as a vaccine vector. To evaluate whether the immunogenicity of MVA might be increased by manipulation of MVA immunomodulatory proteins, the MVA counterpart of B14, protein 183, was characterized. Unlike B14, protein 183 was unstable in eukaryotic cells unless proteasome-mediated protein degradation was inhibited. Furthermore, 183 did not inhibit NF-kappaB activation in response to cytokine stimulation, and did not restore the virulence of VACV strain Western Reserve lacking gene B14R. The instability and non-functionality of 183 are probably explained by a deletion of 6 aa within alpha-helix 6 of the B14 crystal structure.
Insights
Modified Vaccinia Ankara (MVA) protein 183 is unstable and does not inhibit NF-kappaB activation, unlike its Vaccinia virus counterpart B14. This suggests MVA
Area of Science:
- Virology
- Immunology
- Molecular Biology
Background:
- Vaccinia virus (VACV) utilizes proteins like B14 to counteract host innate immunity by inhibiting nuclear factor kappaB (NF-kappaB) activation.
- Modified Vaccinia Ankara (MVA), an attenuated VACV strain, is a promising vaccine vector, but its immunogenicity may be enhanced by modifying its proteins.
Purpose of the Study:
- To characterize MVA protein 183, the counterpart of VACV B14, and assess its function in modulating host immune responses.
- To determine if protein 183 can inhibit NF-kappaB activation and restore virulence in VACV.
Main Methods:
- Protein stability assays in eukaryotic cells.
- Assessment of NF-kappaB activation in response to cytokine stimulation.
- Virulence restoration assays in VACV strains lacking the B14R gene.
Main Results:
- MVA protein 183 exhibited instability in eukaryotic cells, requiring proteasome inhibition for stability.
- Protein 183 failed to inhibit NF-kappaB activation.
- Protein 183 did not restore virulence to VACV lacking the B14R gene.
- A 6 amino acid deletion in alpha-helix 6 of protein 183 likely explains its instability and lack of function.
Conclusions:
- MVA protein 183 is functionally distinct from VACV B14 due to instability and inability to inhibit NF-kappaB.
- The structural difference, specifically the deletion in alpha-helix 6, underlies the functional deficiency of MVA protein 183.
- These findings provide insights into MVA's immunomodulatory mechanisms and potential for vaccine vector development.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Leaky Scanning
Inhibitors Of Virion Release
In-vitro Mutagenesis

